期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 18, 页码 -出版社
MDPI
DOI: 10.3390/ijms231810302
关键词
drug treatment; hypercoagulation; metabolic disease; non-esterified fatty acids; thrombosis; zinc
资金
- Leverhulme Trust [RPG-2017-214]
- Biotechnology and Biological Sciences Research Council [BB/J006467/1, BB/V014684/1]
- British Heart Foundation [FS/20/3/34956]
The actions of Zn2+ in blood plasma are crucial for blood coagulation and are regulated by human serum albumin (HSA) and non-esterified fatty acids (NEFAs). Elevated NEFA concentrations, as seen in obesity and diabetes, can lead to dysregulation of plasma Zn2+ binding, resulting in hypercoagulation. Lifestyle changes, dietary modifications, and drugs that affect NEFA levels may help in managing this dysregulation.
The initiation, maintenance and regulation of blood coagulation is inexorably linked to the actions of Zn2+ in blood plasma. Zn2+ interacts with a variety of haemostatic proteins in the bloodstream including fibrinogen, histidine-rich glycoprotein (HRG) and high molecular weight kininogen (HMWK) to regulate haemostasis. The availability of Zn2+ to bind such proteins is controlled by human serum albumin (HSA), which binds 70-85% of plasma Zn2+ under basal conditions. HSA also binds and transports non-esterified fatty acids (NEFAs). Upon NEFA binding, there is a change in the structure of HSA which leads to a reduction in its affinity for Zn2+. This enables other plasma proteins to better compete for binding of Zn2+. In diseases where elevated plasma NEFA concentrations are a feature, such as obesity and diabetes, there is a concurrent increase in hypercoagulability. Evidence indicates that NEFA-induced perturbation of Zn2+-binding by HSA may contribute to the thrombotic complications frequently observed in these pathophysiological conditions. This review highlights potential interventions, both pharmaceutical and non-pharmaceutical that may be employed to combat this dysregulation. Lifestyle and dietary changes have been shown to reduce plasma NEFA concentrations. Furthermore, drugs that influence NEFA levels such as statins and fibrates may be useful in this context. In severely obese patients, more invasive therapies such as bariatric surgery may be useful. Finally, other potential treatments such as chelation therapies, use of cholesteryl transfer protein (CETP) inhibitors, lipase inhibitors, fatty acid inhibitors and other treatments are highlighted, which with additional research and appropriate clinical trials, could prove useful in the treatment and management of thrombotic disease through amelioration of plasma Zn2+ dysregulation in high-risk individuals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据